DaBlaCa-13 Study: Mitomycin Chemoresection in Bladder Cancer by Dr. Milap Shah

Welcome to Day 2 of the Cancer Research and Statistic Foundation’s 05th Knowledge Series for Genitourinary Cancers - Best of 2023! This prestigious event, held on 12th May 2024 at The Pride Aero City Delhi, is supported by the Institute of Pulmonology Medical Research & Development and the Sunrise Oncology Centre.

In this session, we feature Dr. Milap Shah from Ahmedabad, presenting the highly anticipated results of the DaBlaCa-13 Study. This groundbreaking randomized controlled trial explores the oncological outcomes of short-term, intensive chemoresection using Mitomycin for patients with nonmuscle invasive bladder cancer (NMIBC). Dr. Shah’s presentation sheds light on the primary outcomes of this study, highlighting the efficacy of Mitomycin in bladder cancer treatment and offering new perspectives on non-invasive treatment options.

Key Topics Covered in This Session:

DaBlaCa-13 Study Overview:
An in-depth look at the design and methodology of this pivotal study.

Mitomycin Chemoresection:
The role of short-term, intensive chemoresection using Mitomycin in managing NMIBC.

Primary Outcomes:
Key findings on oncological outcomes, recurrence rates, and progression data.

Clinical Implications:
How this study can reshape the treatment landscape for nonmuscle invasive bladder cancer, offering less invasive yet effective solutions for patients.

This session is essential viewing for oncologists, urologists, cancer researchers, and healthcare professionals involved in bladder cancer treatment. It also provides valuable insights for patients and caregivers seeking the latest advancements in bladder cancer care.

About Cancer Research and Statistic Foundation (CRS):
The CRS Foundation is committed to advancing cancer research and improving patient care through education, collaboration, and innovation. Our Knowledge Series events bring together experts from around the world to share the latest in cancer treatment and research.

About Our Partners:

Institute of Pulmonology Medical Research & Development: A leading institution advancing research in pulmonology and oncology.
Sunrise Oncology Centre: A premier center for cancer treatment and research, dedicated to delivering cutting-edge care.
Stay tuned for more sessions from the Best of 2023 series, showcasing the latest breakthroughs in genitourinary cancers. Subscribe for updates, and follow us on social media for more insights from leading experts.

Hashtags:
#CancerResearch #BladderCancer #DaBlaCa13Study #MitomycinTreatment #CRSFoundation #GenitourinaryCancers #CancerTreatment #NonmuscleInvasiveBladderCancer #MedicalConference2024 #OncologyResearch #SunriseOncologyCentre #InstituteOfPulmonology